Silexion Therapeutics Corp. has confirmed that SIL204 can inhibit a wide range of KRAS mutations in human cancer cell lines with high rates of inhibition ranging from 83.5% to 99.7%. This includes the first evidence of activity against gastric cancer, expanding the potential therapeutic reach of the drug. The drug has shown significant activity against mutations such as G12R, which is present in 17% of pancreatic cancer cases and has been difficult to inhibit with other treatments. These findings support the development of SIL204 as a comprehensive pan-KRAS inhibitor for various cancer types.

The preclinical studies also revealed that SIL204 has exceptional potency across all cell lines, with IC50 values ranging from 23.4-85.3 nM. The drug demonstrated the highest activity in lung cancer cells with a G12A mutation, showing 99.7% inhibition. Additionally, the drug showed promising results in colorectal cancer and gastric cancer cell lines, further validating its potential to treat multiple cancer types. The Company plans to advance SIL204 to Phase 2/3 clinical trials in 2026, with regulatory submissions expected later this year and in early 2026.

Read more at GlobeNewswire: Silexion Therapeutics Announces Positive New Human Cell